EVOQ Therapeutics

EVOQ Therapeutics is a private, preclinical-stage biotech founded in 2016, headquartered in Ann Arbor, Michigan, with a presence in San Diego. The company's breakthrough is the NanoDisc technology, a targeted antigen delivery system that aims to treat autoimmune diseases at their root cause by reprogramming the immune system. EVOQ has established significant partnerships with major pharmaceutical companies like Sanofi and Gilead and is advancing eight programs toward clinical development. Its approach promises enhanced efficacy with simple subcutaneous administration.

Proprietary NanoDisc technology for targeted delivery of disease-specific antigens to dendritic cells in lymph nodes, liver, and spleen to restore immune tolerance.

EVOQ competes in the antigen-specific immunotherapy space for autoimmune diseases, facing competition from other biotechs and large pharma developing tolerogenic vaccines, cell therapies, and antibody-based approaches. Its key differentiator is the targeted delivery and claimed superior efficacy of its NanoDisc platform.